Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
EVT Stock Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
Evotec Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €24.97 |
52 Week High | €45.83 |
52 Week Low | €20.16 |
Beta | 0.98 |
1 Month Change | -2.61% |
3 Month Change | -0.08% |
1 Year Change | -32.22% |
3 Year Change | 6.21% |
5 Year Change | 99.36% |
Change since IPO | 58.54% |
Recent News & Updates
Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?
While Evotec SE ( ETR:EVT ) might not be the most widely known stock at the moment, it saw a double-digit share price...
Is Evotec (ETR:EVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Shareholder Returns
EVT | DE Life Sciences | DE Market | |
---|---|---|---|
7D | 0.4% | 1.1% | -0.4% |
1Y | -32.2% | -12.3% | -12.4% |
Return vs Industry: EVT underperformed the German Life Sciences industry which returned -11.6% over the past year.
Return vs Market: EVT underperformed the German Market which returned -12.9% over the past year.
Price Volatility
EVT volatility | |
---|---|
EVT Average Weekly Movement | 8.9% |
Life Sciences Industry Average Movement | 7.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 3.4% |
Stable Share Price: EVT is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: EVT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 4,354 | Werner Lanthaler | https://www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals.
Evotec Fundamentals Summary
EVT fundamental statistics | |
---|---|
Market Cap | €4.41b |
Earnings (TTM) | €89.57m |
Revenue (TTM) | €649.62m |
49.3x
P/E Ratio6.8x
P/S RatioIs EVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EVT income statement (TTM) | |
---|---|
Revenue | €649.62m |
Cost of Revenue | €496.46m |
Gross Profit | €153.16m |
Other Expenses | €63.59m |
Earnings | €89.57m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
Earnings per share (EPS) | 0.51 |
Gross Margin | 23.58% |
Net Profit Margin | 13.79% |
Debt/Equity Ratio | 27.7% |
How did EVT perform over the long term?
See historical performance and comparisonValuation
Is Evotec undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
12.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EVT (€24.97) is trading below our estimate of fair value (€28.65)
Significantly Below Fair Value: EVT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: EVT is poor value based on its PE Ratio (49.3x) compared to the European Life Sciences industry average (46.4x).
PE vs Market: EVT is poor value based on its PE Ratio (49.3x) compared to the German market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: EVT is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: EVT's PB Ratio (3.4x) is in line with the XE Life Sciences industry average.
Future Growth
How is Evotec forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
42.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVT's forecast earnings growth (42.6% per year) is above the savings rate (-0.05%).
Earnings vs Market: EVT's earnings (42.6% per year) are forecast to grow faster than the German market (7.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EVT's revenue (15.5% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: EVT's revenue (15.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EVT's Return on Equity is forecast to be low in 3 years time (4.5%).
Past Performance
How has Evotec performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
31.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVT has a large one-off loss of €73.7M impacting its March 31 2022 financial results.
Growing Profit Margin: EVT's current net profit margins (13.8%) are higher than last year (8.1%).
Past Earnings Growth Analysis
Earnings Trend: EVT's earnings have grown significantly by 31.8% per year over the past 5 years.
Accelerating Growth: EVT's earnings growth over the past year (113.7%) exceeds its 5-year average (31.8% per year).
Earnings vs Industry: EVT earnings growth over the past year (113.7%) exceeded the Life Sciences industry 50.8%.
Return on Equity
High ROE: EVT's Return on Equity (6.8%) is considered low.
Financial Health
How is Evotec's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: EVT's short term assets (€1.1B) exceed its short term liabilities (€339.6M).
Long Term Liabilities: EVT's short term assets (€1.1B) exceed its long term liabilities (€535.5M).
Debt to Equity History and Analysis
Debt Level: EVT has more cash than its total debt.
Reducing Debt: EVT's debt to equity ratio has increased from 2.6% to 27.7% over the past 5 years.
Debt Coverage: EVT's debt is well covered by operating cash flow (50.6%).
Interest Coverage: EVT earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Evotec current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EVT has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
5.9yrs
Average management tenure
CEO
Werner Lanthaler (53 yo)
13.17yrs
Tenure
€4,614,000
Compensation
Dr. Werner Lanthaler, MBA, has been the Chief Executive Officer of Evotec SE (formerly known as Evotec AG) since March 2009 and serves as its Chairman of Management Board. Dr. Lanthaler has an outstanding...
CEO Compensation Analysis
Compensation vs Market: Werner's total compensation ($USD4.93M) is above average for companies of similar size in the German market ($USD2.37M).
Compensation vs Earnings: Werner's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: EVT's management team is seasoned and experienced (5.9 years average tenure).
Board Members
Experienced Board: EVT's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.
Top Shareholders
Company Information
Evotec SE's employee growth, exchange listings and data sources
Key Information
- Name: Evotec SE
- Ticker: EVT
- Exchange: XTRA
- Founded: 1993
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €4.412b
- Shares outstanding: 176.70m
- Website: https://www.evotec.com
Number of Employees
Location
- Evotec SE
- Essener Bogen 7
- Hamburg
- Hamburg
- 22419
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/23 00:00 |
End of Day Share Price | 2022/05/23 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.